首页 正文

Published Erratum The journal of prevention of Alzheimer's disease. 2025 Jun 5:100217. doi: 10.1016/j.tjpad.2025.100217 0.02024

Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082]

“沙比瑞单抗(ACU193)治疗早期阿尔茨海默病患者后的生物流体生物标志物变化:INTERCEPT-AD一期试验的撤回声明”[J Prev Alzheimers Dis 2025;12(4): 100082]的勘误表 翻译改进

Erika N Cline  1, Daniel Antwi-Berko  2, Karen Sundell  3, Elizabeth Johnson  3, Maddelyn Hyland  3, Hao Zhang  3, Hugo Vanderstichele  3, June Kaplow  3, Robert A Dean  3, Erik Stoops  4, Eugeen Vanmechelen  4, Marleen J A Koel-Simmelink  2, Charlotte E Teunissen  2, Gopalan Sethuraman  3, Todd Feaster  3, Eric Siemers  3, Jasna Jerecic  3

作者单位 +展开

作者单位

  • 1 Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA. Electronic address: ecline@acumenpharm.com.
  • 2 Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
  • 3 Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA.
  • 4 ADx NeuroSciences, Technologiepark 6, Gent, Belgium.
  • DOI: 10.1016/j.tjpad.2025.100217 PMID: 40480947

    摘要 中英对照阅读

    Copyright © The journal of prevention of Alzheimer's disease. 中文内容为AI机器翻译,仅供参考!

    相关内容

    期刊名:The journal of prevention of alzheimer's disease

    缩写:

    ISSN:2426-0266

    e-ISSN:

    IF/分区:0.0/

    文章目录 更多期刊信息

    全文链接
    引文链接
    复制
    已复制!
    推荐内容
    Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082]